Studies on alginate-chitosan microcapsules and renal arterial embolization in rabbits.
Spherical and well-dispersed alginate-chitosan microcapsules, with a mean diameter of 77.28+/-0.93 microm (n=3), were prepared by the emulsification-gelation method. Adriamycin hydrochloride (ADM) was used as a model drug to investigate the drug loading capacity and release characteristics of the microcapsules. The drug/carrier ratio and chitosan concentration influenced the encapsulation efficiency of adriamycin. The adriamycin release from microcapsules was obviously different in 0.1 mol/l HCl from that in phosphate-buffered saline (PBS, pH 7.4). The drug was completely and rapidly released in 0.1 mol/l HCl, while it showed a sustained release after a burst release in PBS. The increase in chitosan concentration had no effect on adriamycin release in PBS. Using sulforhodamin B (SRB)-staining survival assay, the inhibition of adriamycin alginate-chitosan microcapsules (ADM-ACM) to different cancer cell lines (human BGC-823 cells, Bel-7402 cells and Hela cells) in vitro was determined. The inhibitory rate of ADM-ACM suspension to the three cell lines significantly outran that of ADM solution, no matter at high or low concentration. The effects of blank alginate-chitosan microcapsules (BACM) on renal arterial embolization were examined with transcatheter arterial embolization in rabbits. The angiogram and histopathological results indicated the blank microcapsules had excellent short- and long-term effects on renal arterial embolization.
Li
Sha
S
Department of Pharmaceutics, School of Pharmacy, Peking University, 100083 Beijing, China.
Wang
Xiang-tao
XT
Zhang
Xiao-bin
XB
Yang
Ren-jie
RJ
Zhang
Hong-zhi
HZ
Zhu
Lin-zhong
LZ
Hou
Xin-pu
XP
D000464:Alginates / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D002214:Capsules; D002455:Cell Division / Q000187:drug effects; D002686:Chitin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology*; D048271:Chitosan; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000737:chemistry / Q000494:pharmacology*; D004337:Drug Carriers / Q000737:chemistry / Q000494:pharmacology; D004621:Embolization, Therapeutic / Q000379:methods*; D005260:Female; D020723:Glucuronic Acid; D006603:Hexuronic Acids; D006801:Humans; D008297:Male; D010316:Particle Size; D011817:Rabbits; D012077:Renal Artery / Q000187:drug effects*; D014407:Tumor Cells, Cultured
D000464:Alginates; D002214:Capsules; D004337:Drug Carriers; D006603:Hexuronic Acids; D002686:Chitin; D004317:Doxorubicin; D020723:Glucuronic Acid; D048271:Chitosan